EnteraSense is developing an innovative sensor technology to detect and monitor Upper Gastrointestinal Bleeding (UGIB). The company has licensed the technology from Brigham and Women’s Hospital and Harvard Medical School and has augmented the Intellectual Property portfolio with further development of the technology.
The sensor is contained within a capsule which is ingested in the same way as existing capsule products in the market today. The optical-based sensor acquires data from the environment during its transit along the Gastrointestinal tract. The data is then processed by an algorithm to determine if blood is present and sends a signal to an external monitor located near the patient. This new technology will significantly enhance the diagnostic capabilities for GI physicians.
EnteraSense will initially target patients that are at high risk of re-bleed and required prolonged monitoring before been discharged. The product will reduce the number of unnecessary endoscopies currently performed in this patient group, delivering benefits to patients and hospitals.